Precision NanoSystems, now part of Cytiva, is a global leader in ushering in the next wave of genomic medicines in infectious diseases, cancer, and rare diseases. We work with the world’s leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genomic medicines.
Precision NanoSystems, now part of Cytiva, is a global leader in ushering in the next wave of genomic medicines in infectious diseases, cancer, and rare diseases. We work with the world’s leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genomic medicines.
Precision NanoSystems, now part of Cytiva, is a global leader in ushering in the next wave of genomic medicines in infectious diseases, cancer, and rare diseases. We work with the world’s leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genomic medicines.